Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure

Author(s):  Ma Nathan, Perks William, Law Shirley, Iazzetta John, Walker Scott

Issue:  Nov/Dec 2020 - Volume 24, Number 6
View All Articles in Issue

Page(s):  519-527

Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 1
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 2
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 3
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 4
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 5
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 6
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 7
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 8
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure Page 9

Download in electronic PDF format for $65

Abstract:  Finasteride is not commercially available in a liquid format, which stimulated the development of a stable and simple finasteride suspension formulation. The objectives of this work were to develop and test a finasteride suspension for 1) simplicity to compound, 2) pharmaceutical acceptability, 3) stability, and 4) potential for occupational exposure. The stability of commercial 5-mg finasteride tablets (50 mg/150 mL) was evaluated in water, Oral Mix, and OralMix SF in amber polyethylene terephthalate bottles at 25°C or 4°C. Additional stability studies were carried out using sugar-free Finasteride Powder USP in amber polyethylene terephthalate bottles and tablets in water in polypropylene oral syringes. On study days 0, 1, 3, 7, 14, 28, 38, 49, 63, and 90, the finasteride concentration was determined using a validated stability-indicating liquid chromatographic method. The potential occupational airborne exposure was evaluated by attempting to measure finasteride in 1000 liters of room air following shaking and nebulization. Finasteride suspension/dispersion formulations were prepared in water, Oral Mix, and Oral Mix SF from tablets and pure powder. All formulations retained more than 94.3% of the initial finasteride concentration, with 95% confidence, when stored for up to 90 days at room temperature or 4°C. Simulations of occupational exposure failed to demonstrate the presence of finasteride in room air following attempts to nebulize finasteride mixtures. We conclude that 333-µg/mL suspension/dispersions of finasteride in water or Oral Mix products will have more than 94.3% of the initial finasteride concentration remaining after 90 days, regardless of the formulation, container, or storage temperature. Although we could not detect finasteride in room air, given the analytical limits of the study, we estimate that exposure would unlikely exceed 3.6-µg/1000 liters of room air. Nevertheless, since current regulations are based on “no safe limit,” use of primary engineering controls and personal protective equipment as appropriate is recommended.

Related Keywords: Nathan Ma, RPh, HBSc, PharmD, ACPR, MSc, William Perks, RPh, BSc (Pharm), EMBA, Shirley Law, Dip Pharm Tech, John Iazzetta, PharmD, Scott Walker, MScPhm, finasteride, oral suspension, hazardous drug, occupational exposure, workplace safety, stability, vaporization, aerosolization, dispersion, nebulization

Related Categories: ENVIRONMENTAL , STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, PROFESSIONAL ISSUES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Development of Stable and Simple Finasteride 333-μg/mL Suspensions that Minimize Occupational Exposure
Ma Nathan
, Perks William, Law Shirley, Iazzetta John, Walker Scott
Nov/Dec 2020
Pg. 519-527

Stability of Extemporaneously Compounded Nadolol 10-mg/mL Suspension in Oral Mix in Glass and Plastic Bottles and Plastic Syringes
Walsh Andrea
, Ziegler Blake, Lingertat-Walsh Karen, Law Shirley, Walker Scott E
Mar/Apr 2021
Pg. 163-168

Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety
Allen W Chris
, Greeson Nicole MH, Mixon William
Nov/Dec 2020
Pg. 451-458

Safety Standards in Pharmaceutical Compounding, Part 1: The Occupational Safety and Health Administration
Greeson Nicole MH
, Mixon William, Allan W Chris
Jul/Aug 2020
Pg. 270-276

How to Develop and Maintain a Hazardous Drug List
Dillon L Rad
May/Jun 2019
Pg. 182-186

Stability of Venlafaxine Immediate-Release Suspensions
Donnelly Ronald F
, Wong Keith, Goddard Rob, Johanson Christel
Jan/Feb 2011
Pg. 81-84

Basics of Compounding for Hazardous Drugs, Part 2: Regulation and Sources of Contamination
Allen Loyd V Jr
Nov/Dec 2006
Pg. 446-448

Complying with Occupational Safety and Health Administration Regulations: A Guide for Compounding Pharmacists
Mixon Bill
, Nain John
May/Jun 2013
Pg. 182-190

Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations
Visser J Carolina
, ten Seldam Inge E J, van der Linden Isabella J, Hinrichs Wouter L J, Veenendaal Reinier F H, Dijkers Eli C F, Woerdenbag Herman J
May/Jun 2018
Pg. 247-251

Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Kabiche Djamila
, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
Mar/Apr 2017
Pg. 160-163

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions